Results 71 to 80 of about 43,548 (209)
Salvianolic Acid B Prevents Arsenic Trioxide-Induced Cardiotoxicity In Vivo and Enhances Its Anticancer Activity In Vitro [PDF]
, 2013 Clinical attempts to reduce the cardiotoxicity of arsenic trioxide (ATO) without compromising its anticancer activities remain to be an unresolved issue.
Chen, Rongchang +10 more
core +3 more sources
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
British Journal of Pharmacology, EarlyView.Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Down syndrome with microgranular variant of acute promyelocytic leukemia in a child: a case report
Journal of Medical Case Reports, 2007 Background Acute promyelocytic leukemia (APL) accounts for less than 10% of pediatric AML. Cases of APL in Down syndrome (DS) have been described in the literature rarely and it is rarer still to find the microgranular variant (M3v) of APL in trisomy 21 ...
Jain Deepali +2 more
doaj +1 more source
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia [PDF]
, 2014 Acute promyelocytic leukemia (APL) is a hematological malignancy driven by a chimeric oncoprotein containing the C terminus of the retinoic acid receptor-a (RARa) fused to an N-terminal partner, most commonly promyelocytic leukemia protein (PML ...
dos Santos, Guilherme Augusto +2 more
core +1 more source
Cancer Science, EarlyView.FBMTG‐APL2017: First prospective multicenter trial evaluating frontline ATRA‐ATO therapy for newly diagnosed APL in Japan, encompassing both low–intermediate (n = 65) and high‐risk (n = 16) patients. Excellent outcomes (95% CR, 94% 3‐year DFS) with comparable efficacy between risk groups (DFS: 97% vs.
Ken Takase +14 more
wiley +1 more source
Disparities in early death and survival in children, adolescents, and young adults with acute promyelocytic leukemia in California. [PDF]
, 2015 BACKGROUND: Findings from clinical trials and population-based studies have differed with regard to whether mortality within 30 days of diagnosis (early death) of acute promyelocytic leukemia (APL) has decreased in the era of all-trans retinoic acid and ...
Abrahão, Renata +4 more
core +1 more source
Cell Proliferation, EarlyView.We designed a framework for screening clinical drug combinations with anti‐hepatocellular carcinoma (HCC) activity, comprising four parts: primary screening, single‐cell screening, functional validation, and mechanism research. High‐throughput single‐cell screening identifies HY (HHT and YM155) as a potent anti‐HCC drug combination, validated by in ...
Mengmeng Jiang +12 more
wiley +1 more source
Revista Brasileira de Hematologia e HemoterapiaAcute promyelocytic leukemia has good prognosis in view of the high complete remission and survival rates achieved with therapies containing all-trans retinoic acid or arsenic trioxide.
Erick Crespo-Solis +6 more
doaj +1 more source
The miR-223 host non-coding transcript linc-223 induces IRF4 expression in acute myeloid leukemia by acting as a competing endogenous RNA [PDF]
, 2016 Alterations in genetic programs required for terminal myeloid differentiation and aberrant proliferation characterize acute myeloid leukemia (AML) cells.
Bozzoni, Irene +8 more
core +2 more sources
Misleading acute promyelocytic leukemia morphology [PDF]
Blood, 2015 ![Figure][1] An 85-year-old man was admitted with a 4-week history of weakness, vertigo, weight loss, and pallor. Blood cell count showed 3 × 109/L leukocytes, 9 g/dL hemoglobin, 49 × 109/L platelets, and no disseminated intravascular coagulation.
Soraya, Wuillème, Yannick, Le Bris
openaire +2 more sources